M
Mary E. Enama
Researcher at National Institutes of Health
Publications - 41
Citations - 5791
Mary E. Enama is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Vaccination & DNA vaccination. The author has an hindex of 28, co-authored 41 publications receiving 5171 citations. Previous affiliations of Mary E. Enama include Vaccine Research Center.
Papers
More filters
Journal ArticleDOI
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Robert A. Seder,Lee-Jah Chang,Mary E. Enama,Kathryn L Zephir,Uzma N. Sarwar,Ingelise J. Gordon,La Sonji A. Holman,Eric R. James,Peter F. Billingsley,Anusha Gunasekera,Adam D. Richman,Sumana Chakravarty,Anita Manoj,Soundarapandian Velmurugan,Ming Lin Li,Adam Ruben,Tao Li,Abraham G. Eappen,Richard E. Stafford,Sarah H. Plummer,Cynthia S. Hendel,Laura Novik,Pamela Costner,Floreliz Mendoza,Jamie G. Saunders,Martha Nason,Jason H. Richardson,Jittawadee Murphy,Silas A. Davidson,Thomas L. Richie,Martha Sedegah,Awalludin Sutamihardja,Gary A. Fahle,Kirsten E. Lyke,Matthew B. Laurens,Matthew B. Laurens,Mario Roederer,Kavita Tewari,Judith E. Epstein,B. Kim Lee Sim,Julie E. Ledgerwood,Barney S. Graham,Stephen L. Hoffman +42 more
TL;DR: There is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards.
Journal ArticleDOI
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
Scott M. Hammer,Magdalena E. Sobieszczyk,Holly Janes,Shelly Karuna,Mark J. Mulligan,Doug Grove,Beryl A. Koblin,Susan Buchbinder,Michael C. Keefer,Georgia D. Tomaras,Nicole Frahm,John Hural,Chuka Anude,Barney S. Graham,Mary E. Enama,Elizabeth Adams,Edwin DeJesus,Richard M. Novak,Ian Frank,Carter Bentley,Shelly Ramirez,Rong Fu,Richard A. Koup,John R. Mascola,Gary J. Nabel,David C. Montefiori,James G. Kublin,M. Juliana McElrath,Lawrence Corey,Peter B. Gilbert +29 more
TL;DR: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied and had an acceptable side-effect profile.
Journal ArticleDOI
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch,Eli Boritz,Emily E. Coates,Adam DeZure,Patrick J Madden,Pamela Costner,Mary E. Enama,Sarah H. Plummer,LaSonji A. Holman,Cynthia S. Hendel,Ingelise J. Gordon,Joseph P. Casazza,Michelle Conan-Cibotti,Stephen A. Migueles,Randall Tressler,Robert T. Bailer,Adrian B. McDermott,Sandeep Narpala,Sijy O'Dell,Gideon Wolf,Jeffrey D. Lifson,Brandie A. Freemire,Robert J. Gorelick,Janardan P. Pandey,Sarumathi Mohan,Nicolas Chomont,Rémi Fromentin,Tae-Wook Chun,Anthony S. Fauci,Richard M. Schwartz,Richard A. Koup,Daniel C. Douek,Zonghui Hu,Edmund V. Capparelli,Barney S. Graham,John R. Mascola,Julie E. Ledgerwood,Vrc Study Team +37 more
TL;DR: A single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains, demonstrating the virological effect of this neutralizing antibody and highlighting the need for combination strategies to maintain virus suppression.
Journal ArticleDOI
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
Andrew T. Catanzaro,Richard A. Koup,Mario Roederer,Robert T. Bailer,Mary E. Enama,Zoe Moodie,Lin Gu,Julie E. Martin,Laura Novik,Bimal K. Chakrabarti,Bryan T. Butman,Jason G. D. Gall,C. Richter King,Charla A. Andrews,Rebecca L. Sheets,Phillip L. Gomez,John R. Mascola,Gary J. Nabel +17 more
TL;DR: The safety, tolerability, and immunogenicity of a replication-defective recombinant adenovirus serotype 5 (rAd5) vector HIV-1 candidate vaccine was well tolerated but was associated with more reactogenicity at the highest dose.
Journal ArticleDOI
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.
Andrew S. Ishizuka,Kirsten E. Lyke,Adam DeZure,Andrea A. Berry,Thomas L. Richie,Floreliz Mendoza,Mary E. Enama,Ingelise J. Gordon,Lee-Jah Chang,Lee-Jah Chang,Uzma N. Sarwar,Uzma N. Sarwar,Kathryn L Zephir,LaSonji A. Holman,Eric R. James,Peter F. Billingsley,Anusha Gunasekera,Sumana Chakravarty,Anita Manoj,Minglin Li,Adam Ruben,Tao Li,Abraham G. Eappen,Richard E. Stafford,Natasha K C,Tooba Murshedkar,Hope Decederfelt,Sarah H. Plummer,Cynthia S. Hendel,Laura Novik,Pamela Costner,Jamie G. Saunders,Matthew B. Laurens,Christopher V. Plowe,Barbara J. Flynn,William R Whalen,John Paul Todd,Jay Noor,Srinivas S. Rao,Srinivas S. Rao,Kailan Sierra-Davidson,Geoffrey M. Lynn,Judith E. Epstein,Margaret A. Kemp,Gary A. Fahle,Sebastian A. Mikolajczak,Matthew Fishbaugher,Brandon K. Sack,Stefan H. I. Kappe,Silas A. Davidson,Lindsey S. Garver,Niklas K. Björkström,Martha Nason,Barney S. Graham,Mario Roederer,B. Kim Lee Sim,Stephen L. Hoffman,Julie E. Ledgerwood,Robert A. Seder +58 more
TL;DR: It is suggested that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.